Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...